Evaluation of weekly low-dose paclitaxel and carboplatin treatment for patients with platinum-sensitive relapsed ovarian cancer
Authors:
- Yoh WatanabeYWYoh Watanabe
- Hidekatsu NakaiHNHidekatsu Nakai
- Haruhiko UedaHUHaruhiko Ueda
- Hiroshi HoshiaiHHHiroshi Hoshiai
- 28 February 2005
- journal article
- clinical trial
- Published by Elsevier in Gynecologic Oncology
- Vol. 96 (2) , 323-329
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Paclitaxel and Carboplatin as Second-Line Therapy in Women With Platinum-Sensitive Ovarian Carcinoma Treated With Platinum and Paclitaxel as First-Line TherapyAmerican Journal of Clinical Oncology, 2004
- Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel vs. cisplatin and paclitaxel (GOG 158) and an update on GOG0 182-ICON5International Journal of Gynecological Cancer, 2003
- Multicenter, Randomized Trial for Stage IIIB or IV Non–Small-Cell Lung Cancer Using Weekly Paclitaxel and Carboplatin Followed by Maintenance Weekly Paclitaxel or ObservationJournal of Clinical Oncology, 2003
- Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trialThe Lancet, 2002
- First-Line Chemotherapy with Weekly Paclitaxel and Carboplatin for Advanced Ovarian Cancer: A Phase I StudyGynecologic Oncology, 2002
- Retrospective Analysis of Carboplatin and Paclitaxel as Initial Second-Line Therapy for Recurrent Epithelial Ovarian Carcinoma: Application Toward a Dynamic Disease State Model of Ovarian CancerJournal of Clinical Oncology, 2002
- Weekly and monthly regimens of paclitaxel and carboplatin in the management of advanced ovarian cancer. A preliminary report on side effectsInternational Journal of Gynecological Cancer, 2001
- Randomized Intergroup Trial of Cisplatin-Paclitaxel Versus Cisplatin-Cyclophosphamide in Women With Advanced Epithelial Ovarian Cancer: Three-Year ResultsJNCI: Journal of the National Cancer Institute, 2000
- Extended phase II study of paclitaxel as a 3-h infusion in patients with ovarian cancer previously treated with platinumEuropean Journal of Cancer, 1997
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerNew England Journal of Medicine, 1996